InVivo Therapeutics (Nasdaq: NVIV) is a clinical-stage biotechnology company focused on redefining the treatment of spinal cord injury. InVivo’s proprietary and investigational Neuro-Spinal Scaffold, based on technology licensed from Robert S. Langer’s lab at Massachusetts Institute of Technology, is in pivotal clinical studies for acute spinal cord injury. The company is headquartered in Cambridge, MA.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
October 22, 2020
September 11, 2020
April 17, 2020